Veru Inc. Proxy Statement Filed
Ticker: VERU · Form: DEFA14A · Filed: Jun 18, 2024 · CIK: 863894
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Veru Inc. proxy filing out - vote on directors & auditors soon.
AI Summary
Veru Inc. filed a Definitive Additional Materials proxy statement on June 18, 2024. This filing relates to the company's annual meeting of stockholders, where proposals such as the election of directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm will be voted upon. The company is seeking shareholder approval for these routine corporate governance matters.
Why It Matters
This filing provides shareholders with crucial information regarding the company's governance and upcoming voting matters, allowing them to make informed decisions at the annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing for corporate governance matters and does not introduce new financial or strategic risks.
Key Players & Entities
- VERU INC. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- 20240618 (date) — Filing date
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement for Veru Inc., providing information to shareholders for an upcoming meeting.
When was this filing submitted?
The filing was submitted on June 18, 2024.
What are some of the key items to be voted on at the shareholder meeting?
The filing indicates proposals will include the election of directors and the ratification of the independent registered public accounting firm.
Who is Veru Inc.'s independent registered public accounting firm?
PricewaterhouseCoopers LLP is listed as the proposed independent registered public accounting firm to be ratified.
What is Veru Inc.'s primary business sector?
Veru Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Stats: 1,486 words · 6 min read · ~5 pages · Grade level 17.4 · Accepted 2024-06-18 16:17:56
Filing Documents
- d828672ddefa14a.htm (DEFA14A) — 22KB
- g828672g0618094047670.jpg (GRAPHIC) — 2KB
- 0001193125-24-163416.txt ( ) — 26KB
Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to the phase 2b trial of enobosarm, whether enobosarm will enhance weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will enhance weight loss and whether the Company will be successful in its transformation into a late stage biopharmaceutical company focused on obesity and oncology. The words anticipate, believe, could, expect, intend, may, opportunity, plan, predict, potential, estimate, should, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Companys current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward- looking statements contained in this press release because of new information or future events, developments or circumstances. Such forward-looking statements are 3 results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking development; the ability to enroll sufficient numbers of subjects